Precision therapy in advanced urothelial cancer

References

• American Cancer Society. (2018, September 25). Cancer facts and figures 2018 [cited 2018 Dec 12]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf
   Google Scholar
• Sanli O, Dobruch J, Knowles MA, et al. Bladder cancer. Nat Rev Dis Primers. 2017;3:17022.
   PubMed Web of Science ®Google Scholar
• Hedegaard J, Lamy P, Nordentoft I, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016;30(1):27–42.
   PubMed Web of Science ®Google Scholar
• Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014;111(8):3110–3115.
   PubMed Web of Science ®Google Scholar
• Choi W, Ochoa A, McConkey DJ, et al. Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset. Eur Urol. 2017;72(3):354–365.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507(7492): 315–322.
   PubMed Web of Science ®Google Scholar
• Sjodahl G, Lauss M, Lovgren K, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18(12):3377–3386.
   PubMed Web of Science ®Google Scholar
• Warrick JI, Walter V, Yamashita H, et al. FOXA1, GATA3 and PPAR cooperate to drive luminal subtype in bladder cancer: a molecular analysis of established human cell lines. Sci Rep. 2016;6:38531.
   PubMed Web of Science ®Google Scholar
• Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540–556.e25.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Khaira D, et al. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer. 2016;122(5):702–711.
   PubMed Web of Science ®Google Scholar
• Sfakianos JP, Cha EK, Iyer G, et al. Genomic characterization of upper tract urothelial carcinoma. Eur Urol. 2015;68(6):970–977.
   PubMed Web of Science ®Google Scholar
• Carlo MI, Vijai J, Mandelker D, et al. DNA damage repair (DDR) germline mutations in patients (Pts) with urothelial carcinoma (UC). J Clin Oncol. 2018;36(suppl_15):1516.
   Web of Science ®Google Scholar
• Klek S, Heald B, Milinovich A, et al. Genetic counseling (GC) and germline (GL) testing rates after adoption of an integrated clinical cancer genetics (CCG) approach to genomics tumor board (GTB). J Clin Oncol. 2018;36(suppl_15):1511.
   Web of Science ®Google Scholar
• Sadaps M, Funchain P, Mahdi H, et al. Precision oncology in solid tumors: a longitudinal tertiary care center experience. J Clin Oncol. 2018;2:1–11.
   Google Scholar
• Agarwal N, Pal SK, Hahn AW, et al. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer. 2018;124(10):2115–2124.
   PubMed Web of Science ®Google Scholar
• Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: american society of clinical oncology and college of american pathologists joint review. J Clin Oncol. 2018;36(16):1631–1641.
   PubMed Web of Science ®Google Scholar
• Grivas P, Nagy RJ, Pond GR, et al. Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: association with outcomes and evolution with therapy. J Clin Oncol. 2017;25(suppl_6):334.
   Google Scholar
• Borah S, Xi L, Zaug AJ, et al. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science. 2015;347(6225):1006–1010.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Barriuso J. Urine telomerase for diagnosis and surveillance of bladder cancer. Adv Urol. 2012;2012:693631.
   PubMedGoogle Scholar
• Barata PC, Koshkin VS, Funchain P, et al. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann Oncol. 2017;28(10):2458–2463.
   PubMed Web of Science ®Google Scholar
• Hovelson DH, Udager AM, McDaniel AS, et al. Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers reveals discordant genomic and transcriptomic events and unique therapeutic implications. Eur Urol. 2018;74(6):741–753.
   PubMed Web of Science ®Google Scholar
• Yi X, Ma J, Guan Y, et al. The feasibility of using mutation detection in ctDNA to assess tumor dynamics. Int J Cancer. 2017;140(12):2642–2647.
   PubMed Web of Science ®Google Scholar
• Ilie M, Hofman V, Long E, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med. 2014;2(11):107.
   PubMedGoogle Scholar
• Molparia B, Nichani E, Torkamani A. Assessment of circulating copy number variant detection for cancer screening. PLoS One. 2017;12(7):e0180647.
   PubMed Web of Science ®Google Scholar
• Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. Chem Rev. 2007;107(5):1387–1407.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014;4(10):1140–1153.
   PubMed Web of Science ®Google Scholar
• Li Q, Damish A, Frazier ZJ, et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer. Clin Cancer Res. 2018. DOI:10.1158/1078-0432.CCR-18-1001.
   Web of Science ®Google Scholar
• Grivas P. DNA damage response gene alterations in urothelial cancer: ready for practice? Clin Cancer Res. 2018. DOI:10.1158/1078-0432.CCR-18-2512
   Web of Science ®Google Scholar
• Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder dancer. Eur Urol. 2015;68(6):959–967.
   PubMed Web of Science ®Google Scholar
• Liu D, Plimack ER, Hoffman-Censits J, et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol. 2016;2(8):1094–1096.
   PubMed Web of Science ®Google Scholar
• Seiler R, Ashab HAD, Erho N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;72(4):544–554.
   PubMed Web of Science ®Google Scholar
• Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24(22):3664–3671.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Bahleda R, Dienstmann R, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015;33(30):3401–3408.
   PubMed Web of Science ®Google Scholar
• Siefker-Radtke AO, Necchi A, Park SH, et al. First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). J Clin Oncol. 2018;36(suppl_15):4503.
   Web of Science ®Google Scholar
• Joerger M, Cassier P, Penel N, et al. Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression. J Clin Oncol. 2018;36(suppl_6):494.
   Web of Science ®Google Scholar
• Sequist LV, Cassier P, Varga A, et al. Abstract CT326: phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res. 2014;suppl_19:CT326.
   Google Scholar
• Necchi A, Pouessel D, Leibowitz-Amit R, et al. Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA). Ann Oncol. 2018;29(suppl_18):viii319-viii:320.
   Google Scholar
• Yap TA, Omlin A, de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol. 2013;31(12):1592–1605.
   PubMed Web of Science ®Google Scholar
• Eriksson P, Sjodahl G, Chebil G, et al. HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts. Oncotarget. 2017;8(30):48905–48914.
   PubMedGoogle Scholar
• Mooso BA, Vinall RL, Mudryj M, et al. The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence. J Urol. 2015;193(1):19–29.
   PubMed Web of Science ®Google Scholar
• Grivas PD, Day M, Hussain M. Urothelial carcinomas: a focus on human epidermal receptors signaling. Am J Transl Res. 2011;3(4):362–373.
   PubMed Web of Science ®Google Scholar
• Wong YN, Litwin S, Vaughn D, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol. 2012;30(28):3545–3551.
   PubMed Web of Science ®Google Scholar
• Hussain M, Daignault S, Agarwal N, et al. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer. 2014;120(17):2684–2693.
   PubMed Web of Science ®Google Scholar
• Powles T, Huddart RA, Elliott T, et al. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2–positive metastatic bladder cancer. J Clin Oncol. 2017;35(1):48–55.
   PubMed Web of Science ®Google Scholar
• Choudhury NJ, Campanile A, Antic T, et al. Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J Clin Oncol. 2016;34(18):2165–2171.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Werner L, Bamias A, et al. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015;4(6):844–852.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Gay LM, et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res. 2014;20(1):68–75.
   PubMed Web of Science ®Google Scholar
• Mejri N, Sellami R, Lamia C, et al. Status of HER2 over expression in muscle invasive urothelial bladder carcinoma: report of 21 cases. Urol Ann. 2014;6(1):63–67.
   PubMedGoogle Scholar
• Kiss B, Wyatt AW, Douglas J, et al. HER2 alterations in muscle-invasive bladder cancer: patient selection beyond protein expression for targeted therapy. Sci Rep. 2017;7:42713.
   PubMed Web of Science ®Google Scholar
• Pal SK, Agarwal N, Choueiri TK, et al. Comparison of tumor mutational burden (TMB) in relevant molecular subsets of metastatic urothelial cancer (MUC). Ann Oncol. 2017;28(suppl_5):v295–v329.
   Google Scholar
• Koshkin VS, O’Donnell P, Yu EY, et al. Systematic review: targeting HER2 in bladder cancer. Bladder Cancer. 2018;5(1):1–12.
   Web of Science ®Google Scholar
• Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II national cancer institute trial. J Clin Oncol. 2007;25(16):2218–2224.
   PubMed Web of Science ®Google Scholar
• Felsenstein KM, Theodorescu D. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nat Rev Urol. 2018;15(2):92–111.
   PubMed Web of Science ®Google Scholar
• Kim J, Fox C, Peng S, et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest. 2014;124(12):5145–5158.
   PubMed Web of Science ®Google Scholar
• Bryce AH, Kurzrock R, Meric-Bernstam F, et al. Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): preliminary data from mypathway. J Clin Oncol. 2017;35(suppl_6):348.
   Web of Science ®Google Scholar
• Ross RL, McPherson HR, Kettlewell L, et al. PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma. BMC Cancer. 2016;16(1):553.
   PubMedGoogle Scholar
• Millis SZ, Bryant D, Basu G, et al. Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. Clin Genitourin Cancer. 2015;13(1):e37–49.
   PubMed Web of Science ®Google Scholar
• Sathe A, Nawroth R. Targeting the PI3K/AKT/mTOR pathway in bladder cancer. Methods Mol Biol. 2018;1655:335–350.
   PubMedGoogle Scholar
• Bellmunt J, Werner L, Riester M, et al. Somatic copy number abnormalities (SCNAs) and mutations in PI3K/AKT pathway and prognostic significance for overall survival (OS) in platinum-treated locally advanced or metastatic urothelial cancer (UC). J Clin Oncol. 2014;32(4_suppl):358.
   PubMed Web of Science ®Google Scholar
• Cho J, Lee J, Kim J, et al. Loss of tuberous sclerosis complex 2 (TSC2) as a predictive biomarker of response to mTOR inhibitor treatment in patients with hepatocellular carcinoma. Transl Oncol. 2016;9(5):466–471.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski DJ, Choueiri TK, Fay AP, et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2016;22(10):2445–2452.
   PubMed Web of Science ®Google Scholar
• Milowsky MI, Iyer G, Regazzi AM, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int. 2013;112(4):462–470.
   PubMed Web of Science ®Google Scholar
• Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.
   PubMed Web of Science ®Google Scholar
• Niegisch G, Retz M, Thalgott M, et al. Second-line treatment of advanced urothelial cancer with paclitaxel and everolimus in a german phase II trial (AUO Trial AB 35/09). Oncology. 2015;89(2):70–78.
   PubMed Web of Science ®Google Scholar
• Nassim R, Mansure JJ, Chevalier S, et al. Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: a novel strategy for treatment. PLoS One. 2013;8(6):e65257.
   PubMed Web of Science ®Google Scholar
• Mazzola CR, Chin J. Targeting the VEGF pathway in metastatic bladder cancer. Expert Opin Investig Drugs. 2015;24(7):913–927.
   PubMed Web of Science ®Google Scholar
• Fus LP, Gornicka B. Role of angiogenesis in urothelial bladder carcinoma. Cent European J Urol. 2016;69(3):258–263.
   PubMed Web of Science ®Google Scholar
• Deniz H, Karakok M, Yagci F, et al. Evaluation of relationship between HIF-1alpha immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas. Int Urol Nephrol. 2010;42(1):103–107.
   PubMed Web of Science ®Google Scholar
• Fauconnet S, Bernardini S, Lascombe I, et al. Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer. Oncol Rep. 2009;21(6):1495–1504.
   PubMed Web of Science ®Google Scholar
• Kopparapu PK, Boorjian SA, Robinson BD, et al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res. 2013;33(6):2381–2390.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10109):2266–2277.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Gonzalez-Larriba JL, Prior C, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011;22(12):2646–2653.
   PubMed Web of Science ®Google Scholar
• Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the eastern cooperative oncology group. Cancer. 2009;115(18):4090–4095.
   PubMed Web of Science ®Google Scholar
• Grivas PD, Daignault S, Tagawa ST, et al. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014;120(5):692–701.
   PubMed Web of Science ®Google Scholar
• Rini BI, Garrett M, Poland B, et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013;53(5):491–504.
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6(6):327–338.
   PubMed Web of Science ®Google Scholar
• Winer AG, Motzer RJ, Hakimi AA. Prognostic biomarkers for response to vascular endothelial growth factor-targeted therapy for renal cell carcinoma. Urol Clin North Am. 2016;43(1):95–104.
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921.
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–5599.
   PubMed Web of Science ®Google Scholar
• Yu E. From the desk of evan yu: “antibody drug conjugates for urothelial carcinoma, a cool technology with promising results.” UroToday [Internet]. 2018 Apr 02 [cited 2018 Sept 26]. Available from: https://www.urotoday.com/clinical-trials/from-the-editor/103205-antibody-drug-conjugates-or-urothelial-carcinoma-a-cool-technology-with-promising-results.html
   Google Scholar
• Rosenberg JE, Srikala S, Zhang J, et al. Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC). J Clin Oncol. 2018;36(suppl_15):4504.
   Web of Science ®Google Scholar
• Tagawa ST, Faltas B, Lam E, et al. Sacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results. Ann Oncol. 2017;28(suppl_5):295–329.
   Google Scholar
• Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev. 2017;54:58–67.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Staff. FDA alters approved use of two checkpoint inhibitors for bladder cancer 2018. National Cancer Institute [Internet]. 2018 Jul 26. Bethesda (MD): National Institutes of Health; [cited 2018 Aug 18]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2018/bladder-cancer-checkpoint-inhibitor-change
   Google Scholar
• Powles T, Duran I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–757.
   PubMed Web of Science ®Google Scholar
• Powles T, Rodriguez-Vida A, Duran I, et al. A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). J Clin Oncol. 2018;36(suppl_15):4506.
   Web of Science ®Google Scholar
• Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-;abel, single-arm, phase II study. J Clin Oncol. 2018. DOI:10.1200/JCO.18.01148.
   Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920.
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Saci A, Szabo PM, et al. Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: exploratory analysis of the phase ii checkmate 275 study. Ann Oncol. 2017;28(suppl_5):295–329.
   Google Scholar
• Daud AI, Loo K, Pauli ML, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126(9):3447–3452.
   PubMed Web of Science ®Google Scholar
• Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A. 2007;104(10):3967–3972.
   PubMed Web of Science ®Google Scholar
• Snyder A, Nathanson T, Funt SA, et al. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: an exploratory multi-omic analysis. PLoS Med. 2017 May;14(5):e1002309.
   PubMed Web of Science ®Google Scholar
• Plimack ER, Bellmunt J, Gupta S, et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from keynote-012. J Clin Oncol. 2017;33(suppl_15):4502.
   Web of Science ®Google Scholar
• Funt S, Charen AS, Yusko E, et al. Correlation of peripheral and intratumoral T-cell receptor (TCR) clonality with clinical outcomes in patients with metastatic urothelial cancer (mUC) treated with atezolizumab. J Clin Oncol. 2016;34(suppl_15):3005.
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548.
   PubMed Web of Science ®Google Scholar
• Wang L, Saci A, Szabo PM, et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun. 2018;9(1):3503.
   PubMed Web of Science ®Google Scholar
• Teo MY, Seier K, Ostrovnaya I, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit From PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol. 2018;36(17):1685–1694.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Wang H, Hahn NM, et al. Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on outcomes. Eur Urol. 2018;73(5):751–759.
   PubMed Web of Science ®Google Scholar
• Iyer G, Audenet F, Middha S, et al. Mismatch repair (MMR) detection in urothelial carxcinoma (UC) and correlation with immune checkpoint blockade (ICB) response. J Clin Oncol. 2017;35(suppl_15):4511.
   Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (checkmate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–322.
   PubMed Web of Science ®Google Scholar
• Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483–1492.
   PubMed Web of Science ®Google Scholar
• Parikh M, Chong-Xian P, Beckett L, et al. Combination checkpoint immunotherapy and cytotoxic chemotherapy: further results from a phase Ib/II trial of pembrolizumab and docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer. J Clin Oncol. 2018;36(suppl_6):525.
   PubMed Web of Science ®Google Scholar
• Castellano D, Duran Martinez I, Rodriguez-Vida A, et al. A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). Ann Oncol. 2018;29(suppl_8):viii303–viii331.
   Google Scholar
• Gopalakrishnan D, Koshkin VS, Ornstein MC, et al. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag. 2018;14:1019–1040.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. U.S. Food and Drug Administration [Internet]. 2018 May 30 [cited 2018 Dec 12]. Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm560040.htm
   Google Scholar
• American Society of Clinical Oncology. FDA approves larotrectinib for solid tumors with NTRK gene fusions. American Society of Clinical Oncology [Internet]. 2018 Nov 26 [cited 2018 Dec 12]. Available from: https://www.asco.org/advocacy-policy/asco-in-action/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions
   Google Scholar
• Tsimberidou AM, Hong DS, Wheler JJ, et al. Precision medicine: clinical outcomes including long-term survival according to the pathway targeted and treatment period–the impact study. J Clin Oncol. 2018;36(suppl_18):LBA2553–LBA2553.
   Web of Science ®Google Scholar
• Massard C, Michiels S, Ferté C, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the moscato 01 trial. Cancer Discov. 2017;7(6):586–595.
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (shiva): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–1334.
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology. ASCO expands tapur study enrollment after promising initial treatment outcomes seen. American Society of Clinical Oncology [Internet]. 2017 Nov 16 [cited 2018 Dec 12]. Available from: https://www.asco.org/about-asco/press-center/news-releases/asco-expands-tapur-study-enrollment-after-promising-initial
   Google Scholar
• Lee K-H, Song CG. Epigenetic regulation in bladder cancer: development of new prognostic targets and therapeutic implications. Trans Cancer Res. 2017;S677–S688.
   Web of Science ®Google Scholar
• Grivas P, Mortazavi A, Picus J, et al. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer. 2018. DOI:10.1002/cncr.31817.
   Web of Science ®Google Scholar